|
Subject number
|
Age, sex
|
Findings in thyroid ultrasonography
|
TSH (μIU/mL)
|
FT4 (ng/dL)
|
FT3 (pg/mL)
|
L-T4 replacement dose (μg/day)
|
Tg-Ab (IU/mL)
|
TPO-Ab (IU/mL)
|
SUV max
|
Interval Between FDG-PET and thyroid test (days)
|
|---|
|
Diffuse uptake
|
|
1
|
51 F
|
Hetero, Hypo
|
22.43
|
1.06
|
2.20
|
0
|
143
|
22
|
3.322
|
13
|
|
2
|
78 F
|
Hetero
|
6.73
|
0.78
|
2.08
|
0
|
> 4000
|
487
|
8.125
|
11
|
|
3
|
68 F
|
Hetero, Hypo
|
73.06
|
0.57
|
2.37
|
25
|
> 4000
|
16
|
3.741
|
28
|
|
4
|
59 F
|
Hetero
|
6.43
|
0.93
|
3.21
|
0
|
n.a.
|
184
|
6.070
|
64
|
|
5
|
80 M
|
Rough, Hetero
|
28.59
|
1.07
|
2.56
|
0
|
> 4000
|
> 600
|
5.714
|
3
|
|
6
|
86 F
|
Hetero
|
21.04
|
0.68
|
1.75
|
12.5
|
476
|
53
|
3.354
|
1
|
|
7
|
64 F
|
Hetero
|
3.79
|
1.32
|
1.16
|
0
|
122
|
29
|
2.923
|
1
|
|
8
|
66 M
|
Hetero, Hypo
|
8.45
|
0.93
|
2.64
|
0
|
> 4000
|
> 600
|
6.165
|
21
|
|
9
|
78 F
|
Rough, Hetero
|
87.87
|
0.50
|
1.50
|
25
|
n.a.
|
> 600
|
12.023
|
4
|
|
10
|
41 F
|
Rough, Homo
|
46.21
|
0.94
|
1.58
|
125
|
626
|
> 600
|
9.985
|
3
|
|
11
|
43 F
|
Hetero
|
3.24
|
1.31
|
2.49
|
0
|
537
|
332
|
4.113
|
7
|
|
12
|
67 F
|
Rough, Hetero
|
25.11
|
0.94
|
3.04
|
0
|
2940
|
184
|
3.340
|
24
|
|
13
|
63 M
|
Rough, Hetero
|
266.1
|
0.19
|
1.16
|
0
|
1360
|
72
|
3.868
|
19
|
|
Without diffuse uptake
|
|
14
|
74 F
|
Homo
|
0.033
|
1.23
|
3.12
|
0
|
147
|
10
|
2.492
|
10
|
|
15
|
68 F
|
Homo
|
11.01
|
1.09
|
2.45
|
0
|
465
|
8
|
2.364
|
39
|
|
16
|
50 M
|
Homo
|
5.38
|
0.96
|
2.15
|
0
|
18
|
22
|
1.535
|
14
|
|
17
|
80 F
|
Homo
|
12.27
|
1.56
|
0.89
|
100
|
18
|
16
|
1.337
|
1
|
|
18
|
74 M
|
Fine, Homo
|
11.23
|
1.11
|
2.39
|
0
|
16
|
18
|
1.704
|
83
|
- F female, M male, TSH serum thyroid stimulating hormone, FT4 serum free T4, FT3 serum free T3, L-T4 levothyroxine, Tg-Ab anti-thyroglobulin antibody, TPO-Ab anti-thyroid peroxidase antibody, SUVmax maximum standardized uptake, FDG 18F-fluorodeoxyglucose, PET positron emission tomography, F female, M male, Hetero heterogenous, Hypo hypoechoic, Homo homogenous, n.a. not assessed